Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co. Ltd. China-based ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that ...

while Roche recently picked up an FDA breakthrough designation for its PD-L1 inhibitor Tecentriq (atezolizumab) in combination with VEGF inhibitor Avastin (bevacizumab). The latter is currently in ...

Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases -- SCS Microinjector® Provides ...

"This is due to the toxicity of VEGF inhibition. We have an extensive program in this combination and found PFS benefit was observed and then toxicities caught up in the combo arm." Notably ...